The U.S. Commerce Department, under the Trump administration, has launched a national security review of medical imports—including PPE, consumables, and medical devices—to assess reliance on foreign suppliers for critical health products.
Shares of medical technology company Becton, Dickinson and Company (NYSE:BDX)
fell 4.2% in the morning session after RBC Capital initiated coverage on the company with a neutral 'Sector Perform' rating.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
4 analysts have expressed a variety of opinions on Becton Dickinson (NYSE: BDX) over the past quarter, offering a diverse set of opinions from bullish to bearish.
Large-cap stocks have the power to shape entire industries thanks to their size and widespread influence.
With such vast footprints, however, finding new areas for growth is much harder than for smaller, more agile players.
Wall Street’s bearish price targets for the stocks in this article signal serious concerns.
Such forecasts are uncommon in an industry where maintaining cordial corporate relationships often trumps delivering the hard truth.
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns.
Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak competitive positioning.
Let’s dig into the relative performance of BD (NYSE:BDX) and its peers as we unravel the now-completed Q2 surgical equipment & consumables - diversified earnings season.
Medical technology company Becton, Dickinson and Company (NYSE:BDX) met Wall Street’s revenue expectations in Q2 CY2025, with sales up 8.9% year on year to $5.51 billion. The company’s outlook for the full year was close to analysts’ estimates with revenue guided to $21.85 billion at the midpoint. Its non-GAAP profit of $3.68 per share was 8.2% above analysts’ consensus estimates.
Medical technology company Becton, Dickinson and Company (NYSE:BDX) met Wall Street’s revenue expectations in Q2 CY2025, with sales up 8.9% year on year to $5.51 billion. The company’s outlook for the full year was close to analysts’ estimates with revenue guided to $21.85 billion at the midpoint. Its non-GAAP profit of $3.68 per share was 8.2% above analysts’ consensus estimates.
Let's delve into the developments on the US markets one hour before the close of the markets on Thursday. Below, you'll find the top gainers and losers within the S&P500 index during today's session.
Let's have a look at what is happening on the US markets in the middle of the day on Thursday. Below you can find the top S&P500 gainers and losers in today's session.
This week, from August 4th to August 10th, 2025, marks a busy period in the second-quarter earnings season, with hundreds of companies across various sectors scheduled to report their financial results. These earnings calls are crucial events for investors, analysts, and the broader market, as they provide insights into corporate
Becton Dickinson beat Q3 earnings and revenue estimates, raised its FY25 EPS outlook, and saw strong growth in its medical and interventional segments.
U.S. equities slipped midday Thursday as corporate earnings and fresh tariff announcements from President Donald Trump drove divergent moves in heavyweight names.
Thursday's session is showcasing interesting market movements in the S&P500 index, with notable gap up and gap down stocks. Stay updated with the gapping S&P500 stocks in today's session.
Medical technology company Becton, Dickinson and Company (NYSE:BDX)
will be reporting earnings this Thursday before the bell. Here’s what you need to know.
